Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 7, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, ...

Denali Therapeutics, Inc. DNLI announced that the FDA has accepted for review its biologics license application (BLA) for lead-pipeline candidate tividenofusp alfa. The BLA is seeking accelerated ...

Denali's lead drug for Hunter syndrome wins FDA Priority Review, marking a key step toward commercial-stage status.